Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement from statistical significant results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Jean-Pascal Machiels speaks to ecancer about the primary results of the phase 3 KEYNOTE-412 study.nnThe study explores pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma.nnThe results of the study showed an overall baseline characteristic that was well balanced between arms. nnAt data cutoff for the final analysis (May 31, 2022), median time from randomisation to data cutoff was 47.7 mo. There was a favourable trend toward
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)